David Preiss1, Adem Dawed2, Paul Welsh3, Alison Heggie4, Angus G Jones5, Jacqueline Dekker6, Robert Koivula7, Tue H Hansen8, Caitlin Stewart3, Rury R Holman9, Paul W Franks7, Mark Walker4, Ewan R Pearson2, Naveed Sattar3. 1. MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Health, University of Oxford, Oxford, UK. 2. Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, UK. 3. BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. 4. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. 5. NIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK. 6. Department of Epidemiology and Biostatistics, VU Medical Center, Amsterdam, The Netherlands. 7. Department of Clinical Sciences, Genetic and Molecular Epidemiology, Lund University, Malmö, Sweden. 8. Section of Metabolic Genetics, Faculty of Health Sciences, Novo Nordisk Foundation Centre for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. 9. Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Abstract
AIMS: To investigate, in the Carotid Atherosclerosis: Metformin for Insulin Resistance (CAMERA) trial (NCT00723307), whether the influence of metformin on the glucagon-like peptide (GLP)-1 axis in individuals with and without type 2 diabetes (T2DM) is sustained and related to changes in glycaemia or weight, and to investigate basal and post-meal GLP-1 levels in patients with T2DM in the cross-sectional Diabetes Research on Patient Stratification (DIRECT) study. MATERIALS AND METHODS: CAMERA was a double-blind randomized placebo-controlled trial of metformin in 173 participants without diabetes. Using 6-monthly fasted total GLP-1 levels over 18 months, we evaluated metformin's effect on total GLP-1 with repeated-measures analysis and analysis of covariance. In the DIRECT study, we examined active and total fasting and 60-minute post-meal GLP-1 levels in 775 people recently diagnosed with T2DM treated with metformin or diet, using Student's t-tests and linear regression. RESULTS: In CAMERA, metformin increased total GLP-1 at 6 (+20.7%, 95% confidence interval [CI] 4.7-39.0), 12 (+26.7%, 95% CI 10.3-45.6) and 18 months (+18.7%, 95% CI 3.8-35.7), an overall increase of 23.4% (95% CI 11.2-36.9; P < .0001) vs placebo. Adjustment for changes in glycaemia and adiposity, individually or combined, did not attenuate this effect. In the DIRECT study, metformin was associated with higher fasting active (39.1%, 95% CI 21.3-56.4) and total GLP-1 (14.1%, 95% CI 1.2-25.9) but not post-meal incremental GLP-1. These changes were independent of potential confounders including age, sex, adiposity and glycated haemoglobin. CONCLUSIONS: In people without diabetes, metformin increases total GLP-1 in a sustained manner and independently of changes in weight or glycaemia. Metformin-treated patients with T2DM also have higher fasted GLP-1 levels, independently of weight and glycaemia.
AIMS: To investigate, in the Carotid Atherosclerosis: Metformin for Insulin Resistance (CAMERA) trial (NCT00723307), whether the influence of metformin on the glucagon-like peptide (GLP)-1 axis in individuals with and without type 2 diabetes (T2DM) is sustained and related to changes in glycaemia or weight, and to investigate basal and post-meal GLP-1 levels in patients with T2DM in the cross-sectional Diabetes Research on Patient Stratification (DIRECT) study. MATERIALS AND METHODS: CAMERA was a double-blind randomized placebo-controlled trial of metformin in 173 participants without diabetes. Using 6-monthly fasted total GLP-1 levels over 18 months, we evaluated metformin's effect on total GLP-1 with repeated-measures analysis and analysis of covariance. In the DIRECT study, we examined active and total fasting and 60-minute post-meal GLP-1 levels in 775 people recently diagnosed with T2DM treated with metformin or diet, using Student's t-tests and linear regression. RESULTS: In CAMERA, metformin increased total GLP-1 at 6 (+20.7%, 95% confidence interval [CI] 4.7-39.0), 12 (+26.7%, 95% CI 10.3-45.6) and 18 months (+18.7%, 95% CI 3.8-35.7), an overall increase of 23.4% (95% CI 11.2-36.9; P < .0001) vs placebo. Adjustment for changes in glycaemia and adiposity, individually or combined, did not attenuate this effect. In the DIRECT study, metformin was associated with higher fasting active (39.1%, 95% CI 21.3-56.4) and total GLP-1 (14.1%, 95% CI 1.2-25.9) but not post-meal incremental GLP-1. These changes were independent of potential confounders including age, sex, adiposity and glycated haemoglobin. CONCLUSIONS: In people without diabetes, metformin increases total GLP-1 in a sustained manner and independently of changes in weight or glycaemia. Metformin-treated patients with T2DM also have higher fasted GLP-1 levels, independently of weight and glycaemia.
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Brian D Green; Nigel Irwin; Nicola A Duffy; Victor A Gault; Finbarr P M O'harte; Peter R Flatt Journal: Eur J Pharmacol Date: 2006-07-27 Impact factor: 4.432
Authors: Tongzhi Wu; Sony S Thazhath; Michelle J Bound; Karen L Jones; Michael Horowitz; Christopher K Rayner Journal: Diabetes Res Clin Pract Date: 2014-08-12 Impact factor: 5.602
Authors: Emilie Bahne; Morten Hansen; Andreas Brønden; David P Sonne; Tina Vilsbøll; Filip K Knop Journal: Diabetes Obes Metab Date: 2016-07-13 Impact factor: 6.577
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Robert W Koivula; Alison Heggie; Anna Barnett; Henna Cederberg; Tue H Hansen; Anitra D Koopman; Martin Ridderstråle; Femke Rutters; Henrik Vestergaard; Ramneek Gupta; Sanna Herrgård; Martijn W Heymans; Mandy H Perry; Simone Rauh; Maritta Siloaho; Harriet J A Teare; Barbara Thorand; Jimmy Bell; Søren Brunak; Gary Frost; Bernd Jablonka; Andrea Mari; Tim J McDonald; Jacqueline M Dekker; Torben Hansen; Andrew Hattersley; Markku Laakso; Oluf Pedersen; Veikko Koivisto; Hartmut Ruetten; Mark Walker; Ewan Pearson; Paul W Franks Journal: Diabetologia Date: 2014-04-04 Impact factor: 10.122
Authors: Hetal S Shah; Mario Luca Morieri; Santica M Marcovina; Ronald J Sigal; Hertzel C Gerstein; Michael J Wagner; Alison A Motsinger-Reif; John B Buse; Peter Kraft; Josyf C Mychaleckyj; Alessandro Doria Journal: Diabetes Care Date: 2017-11-28 Impact factor: 19.112